Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab [1][3]. Company Overview - Skye Bioscience, Inc. is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025, with a deadline for potential lead plaintiff representatives set for January 16, 2026 [1][2]. - The complaint alleges that the company overstated the efficacy of nimacimab and exaggerated its clinical success likelihood [3]. Financial Impact - Following the release of topline results from the 26-week Phase 2a CBeyond study, which indicated that nimacimab did not meet its primary weight-loss endpoint compared to placebo, Skye's share price plummeted by 60%, falling from $4.75 to $1.90 per share [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's lead product candidate, nimacimab [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from November 4, 2024, to October 3, 2025 [1]. - Allegations include that the effectiveness of nimacimab was overstated, leading to inflated clinical, regulatory, and commercial prospects [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness of its drug nimacimab [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives made false and misleading statements regarding nimacimab, claiming it was more effective than it actually is [6]. - Specific allegations include that nimacimab's clinical, regulatory, and commercial prospects were overstated, leading to materially false public statements [6]. Group 3: Stock Price Impact - Following the announcement on October 6, 2025, that nimacimab did not achieve its primary endpoint in a clinical study, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 per share [7].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the upcoming lead plaintiff deadline for a class action lawsuit, indicating potential compensation for affected investors [1]. Group 1: Class Action Details - The class action pertains to securities purchased between November 4, 2024, and October 3, 2025, with a lead plaintiff deadline set for January 16, 2026 [1]. - Investors who purchased Skye securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [3]. Group 3: Case Allegations - The lawsuit alleges that Skye Bioscience's defendants made materially false and misleading statements regarding the effectiveness and prospects of their product, nimacimab, leading to investor damages when the truth was revealed [4].

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Skye securities during the class period because the Company allegedly misled investors regarding the viability of its lead drug candidate. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? According to the complaint, during the class peri ...

NEW YORK, Dec. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslr ...

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that the company's lead product candidate, nimacimab, was less effective than previously claimed, leading to overstated clinical, regulatory, and commercial prospects [2]. - Defendants' public statements regarding nimacimab were materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025, and they have until January 16, 2026, to seek appointment as lead plaintiff [2]. - The complaint claims that Skye failed to disclose that the efficacy of nimacimab was lower than represented, leading to an overstatement of the drug's clinical and commercial potential [3]. Stock Performance Impact - Following the announcement on October 6, 2025, that the primary endpoint of the Phase 2a study of nimacimab was not met, Skye's stock price fell by $2.85 per share, a decline of 60%, closing at $1.90 [4].

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/skye-bioscience-inc-loss-submission-form/?id=180541&from=3 CLASS PERIOD: Nov ...

NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslr ...